As a result of this, the development and validation of more severe mouse models of DMD have helped to provide more accurate disease patterns in the mouse which may accelerate the evaluation of therapies, including ablation of utrophin expression and using different background strains [11,12]. The gene discussed is UTRN; the disease is Duchenne muscular dystrophy.